Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
May 29, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code:600276 Stock abbreviation:Hengrui Pharma No.:Lin 2025-086

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Suzhou Suncadia Biopharmaceuticals Co., Ltd. (蘇州盛迪亞生物醫藥有限公司), a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司)(the "Company"), received a notice from the National Medical Products Administration (NMPA). The NMPA conditionally approves the Company's self-developed Class 1 innovative drug, Famitinib Malate Capsules, for marketing, to be used in combination with Camrelizumab for Injection is indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug	Camrelizumab for Injection	Famitinib Malate Capsules
Dosage Form	Injection	Capsules
Specification	200mg/bottle	5mg
Registered Category	Class 2.2 therapeutic biological product	Class 1 chemical drug
Application Number	CXSS2300091	CXHS2300110
Prescription/ Non-prescription	Prescription Drug	

Drug	
Approved indication	Famitinib Malate in combination with Camrelizumab for Injection is indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment

II. Approved Indications of the Drug

Camrelizumab for Injection has been approved for nine indications in China, namely:

A. In May 2019, it was approved for the treatment of relapsed or refractory classic hodgkin lymphoma after at least two systematic therapies;

B. In March 2020, it was approved for the treatment of advanced hepatocellular carcinoma after sorafenib and/or oxaliplatin-containing chemotherapy;

C. In June 2020, it was approved for combination with pemetrexed+carboplatin for unresectable locally advanced or metastatic EGFR-mut negative ALK negative 1L non-small cell lung cancer,

D. In June 2020, it was approved for locally advanced or metastatic esophageal squamous cell carcinoma progressed after or intolerable to 1L chemotherapy;

E. In April 2021, it was approved for the treatment of advanced nasopharyngeal carcinoma progressed after or intolerable to 2L+chemotherapy;

F. In June 2021，it was approved for combination with cisplatin+gemcitabine for 1L locally relapsed or metastatic nasopharyngeal carcinoma;

G. In December 2021, it was approved for combination with cisplatin+paclitaxel for 1L unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma,

H. In December 2021, it was approved for combination with carboplatin +paclitaxel for 1L locally advanced or metastatic squamous non-small cell lung cancer;

I. In January 2023, it was approved for combination with Apatinib for 1L unresectable or metastatic hepatocellular carcinoma.

III. Other Information of the Drug

The global incidence and mortality of cervical cancer rank fourth among malignant tumors in women. Early-stage cervical cancer has a good prognosis, but patients with recurrent or metastatic disease have a very poor prognosis.[1] Although chemotherapy has long been widely used as a fundamental method for tumor treatment, it is associated with significant adverse reactions and cumulative toxicity. Long-term use easily leads to drug resistance and other limitations, such as inconvenient administration. In recent years, advances in medicine and surgical techniques, along with continuous improvements in radiotherapy and chemotherapy study, have provided a solid technical foundation for the treatment of recurrent or metastatic cervical cancer. At the same time, significant breakthroughs have been continuously achieved in the fields of immunotherapy and targeted therapy. Combination therapies of targeted and immunotherapy have been approved for use in multiple tumor types, bringing new hope and opportunities for maintenance treatment of recurrent or metastatic cervical cancer.[2]

Camrelizumab for Injection is a humanized anti-PD-1 monoclonal antibody that binds to the human PD-1 receptor and blocks the PD-1/PD-L1 pathway, restoring the body's antitumor immune response and thus forming the basis of cancer immunotherapy. Several PD-1 monoclonal antibodies have been approved and marketed abroad, including pembrolizumab (Merck, brand name Keytruda), nivolumab (Bristol-Myers Squibb, brand name Opdivo), cemiplimab (Regeneron Pharmaceuticals, brand name Libtayo), and dostarlimab (GlaxoSmithKline, brand name Jemperli), among others. Many similar products have also been approved for marketing in China. According to the EvaluatePharma database, the combined global sales of anti-PD-1 antibodies in 2024 amounted to approximately USD 41.546 billion. To date, the total accumulated R&D investment in the Camrelizumab for Injection project is approximately RMB 2,959.47 million.

Famitinib Malate Capsules are a small-molecule multi-targeted tyrosine kinase inhibitor innovatively developed by the Company. Several similar products, such as sorafenib, sunitinib, and pazopanib, have been approved for marketing both in China

and abroad. Sorafenib was developed by Bayer and approved for marketing in the United States in 2005. Sunitinib was developed by Pfizer and approved for marketing in the United States in 2006. Pazopanib was developed by GSK/Novartis and approved for marketing in the United States in 2009. All three multi-targeted inhibitors have also been approved for marketing in China. According to the EvaluatePharma database, the combined global sales of Sorafenib, Sunitinib, and Pazopanib in 2024 amounted to approximately USD 543 million. To date, the total accumulated R&D investment in the Famitinib Malate Capsules project is approximately RMB 255.38 million.

IV. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

May 29, 2025

[1] Guidelines for the Clinical Use of Anti-angiogenic Drugs in Cervical Cancer (2023 Edition). Chinese Journal of Practical Gynecology and Obstetrics. 2023,39(12):1201-1209.

[2] Gynecologic Oncology Group of Minimally Invasive and Noninvasive Medicine Committee of Chinese Medical Doctor Association, et al. Chinese Expert Consensus on Comprehensive Diagnosis and Treatment of Recurrent Cervical Cancer (2022 Edition).Chinese Journal of Cancer Prevention and Treatment, 2022,29(24):1715-1724,1740.